“By the end of this year, we plan to enter clinical trials of a vaccine with a new antigenic composition,” RIA Novosti quotes the words of the deputy director of the center for scientific work, Academician of the Russian Academy of Sciences Denis Logunov.
In September, the Gamaleya Center began developing a Russian mRNA vaccine against coronavirus.
Logunov explained that the main difference between the mRNA platform is that it can start the fight against the virus “almost rapidly, in the first half hour.”